Gallbladder carcinoma: The role of p53 protein overexpression and Ki-67 antigen expression as prognostic markers

HPB

Volumn 6, Issue 3, 2004, Pages 174-180

  Hidalgo Grau, Luis A ^a   Badia, Josep M ^a   Admella Salvador, Carmen ^a   Soler Monsó, Teresa ^a   Canaleta, Josep Feliu ^a   Gubern Nogués, Josep M ^a   Suñol Sala, Javier ^a  

^a HOSPITAL DE MATARÓ   (Spain)

Author keywords

Gallbladder carcinoma; Ki 67 expression; p53 expression

Indexed keywords

KI 67 ANTIGEN; PROTEIN P53; TUMOR MARKER;

ADVANCED CANCER; AGED; ARTICLE; CALCULATION; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CELL NUCLEUS; CHOLECYSTECTOMY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GALLBLADDER CARCINOMA; GENE EXPRESSION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PATHOGENESIS; PROGNOSIS; RATING SCALE; STATISTICAL SIGNIFICANCE; TUMOR DIFFERENTIATION;

EID: 4544341111     PISSN: 1365182X     EISSN: None     Source Type: Journal    
DOI: 10.1080/13651820410025110     Document Type: Article

References (46)

1. Albores-Saavedra J, Henson DE. Tumors of the gallbladder and extrahepatic bile ducts. Atlas of Tumor Pathology, 2nd series. Fascicle 22. Washington: Armed Forces Institute of Pathology (AFIP), 1984.
2. Diamantis I, Karamitopoulou E, Perentes E, Zimmermann A. p53 protein immunoreactivity in extrahepatic bile duct and gallbladder cancer: correlation with tumor grade and survival. Hepatology 1995;22:774-9.
3. Abi-Rached B, Neugut A. Diagnostic and management issues in gallbladder carcinoma. Oncology 1995;9:19-30.
4. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
5. Vogelstein B, Kinzler K. p53 function and dysfunction. Cell 1992;70:523-6.
6. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-78.
7. Hollstein M, Sidransky D, Vogelstein B, Harris C. p53 mutations in human cancers. Science 1991;253:49-53.
8. Iggo R, Gatter K, Bartek J, Lane D, Harris AL. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990;335:675-9.
9. Vogelstein B. Chromosome 17 deletions and p53 mutations in colorectal carcinomas. Science 1989;244:217-21.
10. Sidransky D, Von Eschenbach A, Tsai YC, et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science 1991;25:705-9.
11. Bartkova J, Bartek J, Lukas J. p53 protein alterations in human testicular cancer including pre-invasive intratubular germ-cell neoplasia. Int J Cancer 1991;49:196-202.
12. Cunningham J, Lust JA, Schaid DJ, et al. Expression of p53 and 17p loss in colorectal carcinoma. Cancer Res 1992;52: 1974-980.
13. Wagata T, Shibagaki I, Imamura M, et al. Loss of 17p, mutations of p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinoma. Cancer Res 1993; 53:846-50.
14. Gao H, Wang LD, Zhou Q, Hong JY, Huang TY, Yang CS. p53 tumor suppressor gene mutation in early esophageal precancerous lesions and carcinoma among high-risk populations in Henan, China. Cancer Res 1994;54:4342-6.
15. Sheu LF, Chen A, Tseng HH, et al. Assessment of p53 expression in nasopharyngeal carcinoma. Hum Pathol 1995; 26:375-9.
16. Wistuba II, Gazdar AF, Roa I, Albores-Saavedra J. p53 protein overexpression in gallbladder carcinoma and its precursor lesions: an immunohistochemical study. Hum Pathol 1996;27:360-5.
17. Meyer JS. Cell kinetic measurements in human tumors. Hum Pathol 1982;13:874-7.
18. Garcia RL, Coltrera MD, Gown AM. Analysis of proliferative grade using anti PCNA/Cyclin monoclonal antibodies in fixed, embedded tissues. Am J Pathol 1989; 134:733-9.
19. Hall PA, Levison DA. Review: assessment of cell proliferation in histological material. J Clin Pathol 1990;43: 184-92.
20. Kamel OW, LeBrun DP, Davis RE, Berry GJ, Wamke RA. Growth fraction estimation of malignant lymphomas in formalin-fixed paraffin-embedded tissue using anti-PCNA/cyclin 19A. Correlation with Ki-67 labelling. Am J Pathol 1991;138:1471-7.
21. Skalova A, Lehtonen H, Von Boguslawsky K, Leivo I. Prognostic significance of cell proliferation in mucoepidermoid carcinomas of the salivary gland: clinicopathological study using MIB 1 antibody in paraffin sections. Hum Pathol 1994;25:929-35.
22. Lee S. Differences in cell proliferation and prognostic significance of proliferating cell nuclear antigen and Ki-67 antigen immunoreactivity in in situ and invasive carcinomas of the extrahepatic biliary tract. Cancer 1996; 78: 1881-7.
23. Kamel D, Pääkö P, Nuorva K, Vähäkangas K, Soini Y. p53 and c-erbB-2 protein expression in adenocarcinomas and epithelial dysplasias of the gall bladder. J Pathol 1993;170: 67-72.
24. Wee A, Teh M, Raju GC. Clinical importance of p53 protein in gallbladder carcinoma and its precursor lesions. J Clin Pathol 1994;47:453-6.
25. Teh M, Wee A, Raju GC. An immunohistochemical study of p53 protein in gallbladder and extrahepatic bile duct/ampullary carcinomas. Cancer 1994;74:1542-5.
26. Shrestha ML, Miyake H, Kikutjusi T, Tashiro S. Prognostic significance of Ki-67 and p53 antigen expression in carcinomas of bile duct and gallbladder. J Med Invest 1998;45:95-102.
27. Albores-Saavedra J, Henson DE, Sobin LH. Histological typing of tumours of the gallbladder and extrahepatic bile ducts. In: World Health Organization International Histological Classification of Tumours, 2nd edn, Berlin: Springer-Verlag, 1991;7-21.
28. Hermanek P, Hutter RVP, Sobin LH, Wagner G, Wittekind CH. TNM Atlas. Illustrated Guide to the TNM/pTNM Classification of Malignant Tumours, 4th edn. Berlin: Springer-Verlag, 1997;124-30.
29. Ajiki T, Onoyama H, Yamamoto M, et al. p53 protein expression and prognosis in gallbladder carcinoma and premalignant lesions. Hepatogastroenterology 1996; 43: 521-6.
30. Misra S, Chaturvedi A, Goel MM, et al. Overexpression of p53 protein in gallbladder carcinoma in North India. Eur J Surg Oncol 2000;26:164-7.
31. Kim YW, Huh SH, Park YK, Yoon TY, Lee SM, Hong SH. Expression of the c-erb-B2 and p53 protein in gallbladder carcinomas. Oncol Rep 2001;8:1127-32.
32. Li X, Hui AM, Shi YZ, Takayama T, Makuuchi M. Reduced p21 expression is an early event in gallbladder carcinogenesis and is of prognostic significance for patients with carcinomas of the gallbladder. Hum Pathol 2001;32: 771-7.
33. Itoi T, Watanabe H, Ajioka Y, et al. APC, K-ras codon 12 mutations and p53 gene expression in carcinoma and adenoma of the gall-bladder suggest two genetic pathways in gall-bladder carcinogenesis. Pathol Int 1996;46:330-40.
34. Wistuba II, Miquel JF, Gazdar AF, Albores Saavedra J. Gallbladder adenomas have molecular abnormalities different from those present in gallbladder carcinomas. Hum Pathol 1999;30:21-5.
35. Hanada K, Itoh M, Fujii K, et al. TP53 mutations in stage I gallbladder carcinoma with special attention to growth patterns. Eur J Cancer 1997;33:1136-40.
36. Lee CS, Pirdas A. p53 protein immunoreactivity in cancers of the gallbladder, extrahepatic bile ducts and ampulla of Vater. Pathology 1995;27:117-20.
37. Washington K, Gottfried MR. Expression of p53 in adenocarcinoma of the gallbladder and bile ducts. Liver 1996;16: 99-104.
38. Roa I, Vilaseca M, Araya J, et al. p53 tumour suppressor gene protein expression in early and advanced gallbladder carcinoma. Histopathology 1997;31:226-30.
39. Itoi T, Watanabe H, Yoshida M, Ajioka Y, Nishikura K, Saito T. Correlation of p53 protein expression with gene mutation in gallbladder carcinomas. Pathol Int 1997;47: 525-30.
40. Roa I, Villaseca M, Araya JC, et al. DNA ploidy pattern and tumor suppressor gene p53 expression in gallbladder carcinoma. Cancer Epidemiol Biomarkers Prev 1997;6:547-50.
41. Auvinen A, Isola J, Visakorpi T, Koivula T, Virtanen S, Hakama M. Overexpression of p53 and long-term survival in colon carcinoma. Br J Cancer 1994;70:293-6.
42. Esrig D, Elmajian D, Groshen S, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994;331:1259-64.
43. Takei K, Watanabe H, Itoi T, Saito T. p53 and Ki-67 immunoreactivity and nuclear morphometry of " carcinoma-in-adenoma" and adenoma of the gall-bladder. Pathology 1996;46:908-17.
44. Tanno S, Obara T, Fujii T, et al. Proliferative potential and K-ras mutation in epithelial hyperplasia of the gallbladder in patients with anomalous pancreaticobiliary ductal union. Cancer 1998;83:267-75.
45. Yanagisawa N, Mikami T, Koike K, Okayasu I. Enhanced cell kinetics, p53 accumulation and high p21WAF1 expression in chronic cholecystitis: comparison with background mucosa of gallbladder carcinomas. Histopathology 2000;36:54-61.
46. Mikami T, Yanagisawa N, Baba H, Koike M, Okayasu I. Association of Bcl-2 protein expression with gallbladder carcinoma differentiation and progression and its relation to apoptosis. Cancer 1999;85:318-25.